Article in The American journal of drug and alcohol abuse, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Peter TreitlerDepartment of Human Behavior, Research, and Policy, Boston University School of Social Work, Boston, MA, USA.ORCID 0000-0001-9360-2454
Hillary SamplesInstitute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA.
Richard HermidaInstitute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA.
Jennifer MilesInstitute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA.
Elizabeth M StoneInstitute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA.
Stephen CrystalInstitute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA.
Funding
New Jersey Alliance for Clinical Translational Science: NJ ACTSUL1TR003017 · NCATS · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI PANETTIERI, REYNOLD ALEXANDER · 2019 to 2023
$28.9M
Improving MOUD Access, Opioid-Related Outcomes and Equity Among Medicare Beneficiaries with DisabilityR01DA057568 · NIDA · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Stephen Crystal · 2022 to 2026
$3.7M
Multi-level associations between opioid use and overdose: Individual, clinical, and population-based risk factors for fatalityK01DA049950 · NIDA · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI SAMPLES, HILLARY · 2020 to 2024
$981k
Scaling-up Medication for Opioid Use Disorder in Residential Treatment SettingsK99DA057372 · NIDA · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI MILES, JENNIFER · 2024 to 2025
Drug OverdoseMedicaidOpiate Substitution TreatmentOpioid-Related DisordersAdolescentAdultAnalgesics, OpioidBuprenorphineCohort StudiesFemaleHumansMaleMethadoneMiddle AgedNaltrexoneNarcotic AntagonistsAnalgesics, OpioidBuprenorphineMethadoneNaltrexoneNarcotic AntagonistsMedicaidmedications for opioid use disorderMOUDOpioid use disorderOverdose
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Pharmacotherapy and overdose risk following new opioid use disorder diagnosis among Medicaid beneficiaries. · full record | OpenQuestion